Coronary artery disease (CAD) is the world’s leading cause of death, claiming more lives each year than any other condition. In the United States alone, approximately 20 million adults have CAD, and every 40 seconds someone has a heart attack. These statistics are sobering, but they obscure a crucial truth: coronary artery disease is largely preventable, and even after it develops, its progression can be slowed or halted with appropriate intervention.

CAD occurs when the coronary arteries — the blood vessels that supply oxygen and nutrients to the heart muscle itself — become narrowed or blocked by atherosclerosis, a process of plaque buildup within arterial walls. This process begins decades before symptoms appear, often starting in adolescence or early adulthood. By the time chest pain or a heart attack occurs, the disease is typically advanced. This long, silent progression creates both a challenge and an opportunity: the challenge of detecting a disease that causes no symptoms for most of its course, and the opportunity to intervene early through risk factor modification.

The major risk factors for CAD are well established: high LDL cholesterol, low HDL cholesterol, high blood pressure, diabetes, smoking, obesity, physical inactivity, and family history. What’s remarkable is that most of these factors are modifiable through lifestyle changes or medical treatment. The potential for prevention is enormous — studies suggest that addressing known risk factors could prevent 80-90% of coronary events.

Blood testing plays a central role in CAD risk assessment and management. Lipid panels reveal the cholesterol abnormalities that drive atherosclerosis. Glucose and HbA1c tests identify diabetes and prediabetes. Inflammatory markers like high-sensitivity CRP provide additional risk information. Newer tests measuring apolipoprotein B, lipoprotein(a), and other parameters refine risk assessment further. These laboratory values, combined with blood pressure measurement and clinical assessment, enable calculation of cardiovascular risk and guide preventive therapy.

This guide provides a comprehensive overview of coronary artery disease — from the biological processes that cause atherosclerosis to the risk factors that accelerate it, from the symptoms that signal its presence to the tests that detect it, and from lifestyle modifications to medical and interventional treatments. Understanding CAD empowers you to take control of your cardiovascular health.

Quick Summary:

• CAD is the #1 cause of death worldwide — approximately 20 million Americans have it
• Atherosclerosis: Plaque buildup in coronary arteries reduces blood flow to the heart
• Silent for decades: Disease develops long before symptoms appear — prevention is key
• Major risk factors: High LDL, low HDL, hypertension, diabetes, smoking, obesity, family history, physical inactivity
• 80-90% preventable: Most risk factors are modifiable through lifestyle and medical treatment
• Key blood tests: Lipid panel (LDL, HDL, triglycerides), glucose/HbA1c, hs-CRP, Lp(a), apoB
• Symptoms when advanced: Angina (chest pain with exertion), shortness of breath, fatigue
• Acute events: Heart attack (myocardial infarction) occurs when plaque ruptures and artery occludes
• Diagnosis: Stress testing, coronary calcium scoring, CT angiography, cardiac catheterization
• Treatment: Lifestyle modification, statins, aspirin, blood pressure control, revascularization when needed
• Prevention works: Aggressive risk factor control reduces heart attacks and saves lives

---

Understanding Coronary Artery Disease

Anatomy of the Coronary Arteries

The heart is a muscular pump that beats approximately 100,000 times per day, requiring a constant supply of oxygen and nutrients. This supply comes through the coronary arteries — a network of blood vessels that arise from the aorta just above the heart and spread across the heart’s surface before penetrating into the muscle.

The main coronary arteries include:

• Left main coronary artery: A short trunk that quickly divides into two major branches
• Left anterior descending (LAD): Supplies the front and bottom of the left ventricle and the septum; often called “the widow maker” because blockage here is particularly dangerous
• Left circumflex: Wraps around to supply the side and back of the left ventricle
• Right coronary artery (RCA): Supplies the right ventricle and the bottom of the left ventricle; also supplies the electrical conduction system in most people

When these arteries become narrowed or blocked, the heart muscle they supply is deprived of oxygen — a condition called ischemia. If ischemia is severe or prolonged, heart muscle cells die — this is a heart attack (myocardial infarction).

What Is Atherosclerosis?

Atherosclerosis is the disease process underlying CAD. It is not simply a matter of cholesterol “clogging” arteries like grease in a pipe. Rather, atherosclerosis is an active, inflammatory disease process that develops within the arterial wall over decades.

Initiation: The process begins with injury or dysfunction of the endothelium — the thin layer of cells lining the artery. Risk factors like high blood pressure, smoking, high blood sugar, and disturbed blood flow at branch points all damage the endothelium. This damage makes the endothelium more permeable and triggers inflammatory responses.

Lipid accumulation: LDL cholesterol particles enter the arterial wall through the damaged endothelium. Once inside, LDL becomes oxidized and triggers inflammatory responses. The body sends immune cells (monocytes, which become macrophages) to clean up the oxidized LDL, but these cells become engorged with lipid and transform into “foam cells.” Collections of foam cells form fatty streaks — the earliest visible lesions of atherosclerosis, present in many teenagers.

Plaque formation: Over time, the fatty streak evolves into a more complex atherosclerotic plaque. Smooth muscle cells migrate into the area and form a fibrous cap over the lipid core. The plaque grows larger, progressively narrowing the arterial lumen. Calcium deposits accumulate, hardening the plaque — the “hardening of the arteries” of common parlance.

Plaque vulnerability: Not all plaques are equal in their danger. Some plaques are stable — they have thick fibrous caps, smaller lipid cores, and less inflammation. These plaques may narrow the artery significantly but are less likely to rupture. Other plaques are vulnerable or unstable — they have thin fibrous caps, large lipid cores, and intense inflammation. These plaques are prone to rupture, even if they don’t severely narrow the artery.

How Heart Attacks Happen

Most heart attacks don’t occur because a gradually growing plaque finally blocks the artery completely. Instead, they occur when a vulnerable plaque ruptures:

1. The thin fibrous cap of an unstable plaque breaks or erodes
2. The lipid core is exposed to blood
3. Platelets aggregate at the site, and the coagulation cascade activates
4. A blood clot (thrombus) forms rapidly, often completely occluding the artery within minutes
5. Blood flow to the downstream heart muscle stops
6. Heart muscle begins to die within minutes; permanent damage increases with time

This is why many heart attacks occur suddenly in people who had no prior symptoms — the plaque that ruptured may not have been causing significant narrowing before it ruptured. It’s also why unstable angina and non-ST-elevation heart attacks (where the clot doesn’t completely occlude the artery) are medical emergencies — they indicate an unstable plaque that could completely occlude at any moment.

Stable Angina vs. Acute Coronary Syndromes

CAD manifests clinically in different ways:

Stable angina: When a plaque narrows an artery by about 70% or more, blood flow becomes inadequate during exertion. The individual experiences predictable chest discomfort with physical activity that resolves with rest. The symptoms are “stable” — consistent in character, triggers, and response to rest or nitroglycerin.

Acute coronary syndromes (ACS): This term encompasses unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). These represent a spectrum of severity when a plaque becomes unstable:

• Unstable angina: New or worsening chest pain, often at rest; no cardiac enzyme elevation (no muscle death yet)
• NSTEMI: Similar presentation but with cardiac enzyme elevation indicating muscle damage; the artery is partially occluded or intermittently occluded
• STEMI: Complete arterial occlusion with ongoing muscle death; characterized by specific ECG changes; requires immediate reperfusion

All acute coronary syndromes are medical emergencies requiring immediate evaluation and treatment.

---

Risk Factors for Coronary Artery Disease

Decades of epidemiological research, beginning with the landmark Framingham Heart Study in 1948, have identified the factors that increase CAD risk. Understanding these factors enables risk assessment and targeted prevention. Most risk factors are modifiable, offering powerful opportunities for intervention.

Risk Factor Category	Impact on CAD Risk	Modifiable?
High LDL cholesterol	Primary driver of atherosclerosis; dose-response relationship	Yes
Hypertension	Damages endothelium; increases cardiac workload	Yes
Diabetes	2-4 times increased risk; accelerates atherosclerosis	Partially
Smoking	2-4 times increased risk; damages vessels, promotes clotting	Yes
Obesity	Promotes multiple other risk factors	Yes
Physical inactivity	30-40% higher risk; affects multiple pathways	Yes
Family history	~2 times risk if first-degree relative with premature CAD	No
Age	Risk increases with age (men >45, women >55)	No
Male sex	Higher risk than premenopausal women	No

Non-Modifiable Risk Factors

Age: CAD risk increases with age. For men, risk rises significantly after age 45; for women, after age 55 (or after menopause). However, atherosclerosis begins much earlier — the disease process is underway by young adulthood in most people in developed countries.

Sex: Men develop CAD about 10 years earlier than women on average. Premenopausal women have some protection, likely related to estrogen’s effects on lipids and blood vessels. After menopause, women’s risk rises and eventually equals or exceeds men’s risk. Importantly, CAD is the leading cause of death in women as well as men — it’s not just a “man’s disease.”

Family history: A family history of premature CAD — defined as a first-degree male relative with CAD before age 55 or female relative before age 65 — significantly increases risk. This reflects both genetic factors affecting lipid metabolism, blood pressure, and other pathways, as well as shared lifestyle and environmental exposures.

Genetics: Beyond family history, specific genetic variants affect CAD risk. Familial hypercholesterolemia, caused by mutations affecting LDL receptor function, dramatically increases risk. Elevated lipoprotein(a), largely genetically determined, is an independent risk factor. Genome-wide studies have identified hundreds of genetic variants associated with modest increases in CAD risk.

Modifiable Risk Factors

Dyslipidemia (Abnormal Cholesterol):

• High LDL cholesterol: The primary driver of atherosclerosis. LDL particles carry cholesterol into the arterial wall, initiating and propagating plaque formation. Lowering LDL reduces cardiovascular events in proportion to the magnitude of reduction — “lower is better” with no apparent floor for benefit.
• Low HDL cholesterol: HDL participates in reverse cholesterol transport, removing cholesterol from arterial walls. Low HDL is associated with increased risk, though attempts to raise HDL pharmacologically have not reduced events as expected.
• High triglycerides: Elevated triglycerides are associated with increased CAD risk, particularly when accompanied by low HDL and small, dense LDL particles (the “atherogenic dyslipidemia” pattern common in metabolic syndrome and diabetes).
• Elevated apolipoprotein B (apoB): ApoB represents the total number of atherogenic particles (LDL, VLDL, IDL, Lp(a)). Many experts consider it a better measure of atherogenic risk than LDL-C alone.
• Elevated lipoprotein(a): Lp(a) is a genetically determined LDL variant that promotes both atherosclerosis and thrombosis. Elevated Lp(a) is an independent, causal risk factor present in about 20% of the population.

Hypertension: High blood pressure damages the endothelium, accelerates atherosclerosis, and increases cardiac workload. Both systolic and diastolic pressure matter. Hypertension is the leading risk factor for stroke and a major contributor to CAD. Treatment reduces risk substantially.

Diabetes and Insulin Resistance: Diabetes accelerates atherosclerosis through multiple mechanisms: glycation of proteins, oxidative stress, endothelial dysfunction, dyslipidemia, and inflammation. Diabetics have 2-4 times the CAD risk of non-diabetics. CAD is the leading cause of death in diabetics. Insulin resistance and prediabetes also increase risk, even before frank diabetes develops.

Smoking: Cigarette smoking damages the endothelium, promotes inflammation and oxidation, raises LDL and lowers HDL, increases blood clotting tendency, and causes coronary spasm. Smokers have 2-4 times the CAD risk of non-smokers. Risk declines substantially within 1-2 years of quitting and approaches non-smoker risk after 10-15 years.

Obesity: Excess weight, particularly abdominal obesity, promotes insulin resistance, dyslipidemia, hypertension, and inflammation — a constellation of factors that accelerate CAD. Obesity is also associated with sleep apnea, which independently increases cardiovascular risk.

Physical Inactivity: Sedentary lifestyle is an independent risk factor. Exercise improves lipids, blood pressure, glucose metabolism, weight, and endothelial function. Regular physical activity reduces CAD risk by 30-40%.

Diet: Dietary patterns high in saturated fat, trans fat, and refined carbohydrates promote dyslipidemia and insulin resistance. Diets rich in vegetables, fruits, whole grains, fish, and unsaturated fats (Mediterranean-style or DASH dietary patterns) reduce CAD risk.

Inflammation: Chronic low-grade inflammation contributes to atherosclerosis initiation and progression. Elevated high-sensitivity C-reactive protein (hs-CRP) predicts CAD events independent of cholesterol. Sources of chronic inflammation include obesity, diabetes, periodontal disease, chronic infections, and autoimmune conditions.

Emerging and Novel Risk Factors

Sleep disorders: Obstructive sleep apnea significantly increases CAD risk through mechanisms including hypertension, inflammation, and metabolic dysfunction.

Chronic kidney disease: Even mild CKD accelerates atherosclerosis and dramatically increases cardiovascular mortality.

Autoimmune diseases: Rheumatoid arthritis, lupus, and psoriasis are associated with increased CAD risk, likely related to chronic inflammation.

Mental health: Depression and chronic stress are associated with increased CAD risk through both behavioral pathways (poor diet, smoking, inactivity) and physiological mechanisms (cortisol, inflammation).

Air pollution: Long-term exposure to particulate air pollution increases CAD risk through inflammatory and oxidative mechanisms.

---

Symptoms of Coronary Artery Disease

Angina Pectoris

Angina is the classic symptom of CAD, typically described as:

• Pressure, squeezing, heaviness, or tightness in the chest
• Sometimes described as an “elephant sitting on my chest”
• May radiate to the left arm, neck, jaw, shoulder, or back
• Often accompanied by shortness of breath, sweating, or nausea
• Typically triggered by exertion or emotional stress
• Usually lasts a few minutes and resolves with rest

Not all chest pain is angina. Angina typically has a visceral quality — deep and diffuse rather than sharp and localized. It’s not affected by breathing or position. It’s provoked by consistent levels of exertion and relieved predictably by rest or nitroglycerin.

Atypical Presentations

Many individuals, particularly women, diabetics, and the elderly, present with atypical symptoms:

• Shortness of breath without chest pain
• Fatigue or weakness
• Nausea or indigestion
• Back, shoulder, or jaw discomfort without chest symptoms
• Lightheadedness

Diabetic neuropathy may mask typical anginal symptoms. Women are more likely than men to experience atypical symptoms. These atypical presentations can delay diagnosis and treatment.

Silent Ischemia

Some individuals have objective evidence of ischemia on testing but no symptoms — “silent ischemia.” This is particularly common in diabetics. Silent ischemia carries the same prognostic significance as symptomatic ischemia.

Heart Attack Symptoms

A heart attack (myocardial infarction) typically presents with:

• Intense chest pain or pressure lasting more than a few minutes
• Pain not relieved by rest or nitroglycerin
• Associated symptoms: sweating, nausea, shortness of breath, lightheadedness
• Sense of impending doom

Heart attack is a medical emergency. Prompt treatment saves lives and preserves heart muscle. Anyone experiencing these symptoms should call emergency services immediately.

---

The Role of Blood Testing

Blood tests are fundamental to CAD risk assessment, diagnosis, and management.

Lipid Panel

The standard lipid panel includes:

Total cholesterol: The sum of all cholesterol in blood. Provides a general picture but doesn’t distinguish atherogenic from protective components.

LDL cholesterol (LDL-C): The primary target of therapy. LDL carries cholesterol into arterial walls, driving atherosclerosis. Usually calculated rather than directly measured; can be inaccurate when triglycerides are very high.

HDL cholesterol (HDL-C): “Good” cholesterol. HDL participates in reverse cholesterol transport. Low HDL is a risk factor; very high HDL may not be as protective as once thought.

Triglycerides: Elevated triglycerides are associated with increased risk, particularly in the context of metabolic syndrome. Very high triglycerides also risk pancreatitis.

Non-HDL cholesterol: Total cholesterol minus HDL. Represents all atherogenic lipoproteins (LDL + VLDL + IDL + Lp(a)). A useful secondary target, especially when triglycerides are elevated.

Advanced Lipid Testing

Apolipoprotein B (apoB): Directly measures the number of atherogenic particles. Each LDL, VLDL, IDL, and Lp(a) particle contains one apoB molecule. ApoB may be a better predictor of risk than LDL-C, particularly when there’s discordance between LDL-C and particle number (as in metabolic syndrome).

Lipoprotein(a) [Lp(a)]: A genetically determined LDL variant with additional apolipoprotein(a) attached. Elevated Lp(a) is an independent, causal risk factor. Should be measured at least once in adults being assessed for cardiovascular risk. Levels are largely fixed by genetics; lifestyle and most medications have little effect. Knowing Lp(a) is elevated informs more aggressive management of other risk factors.

LDL particle number (LDL-P): Some labs offer direct measurement of LDL particle concentration. Like apoB, may be superior to LDL-C when discordant.

LDL particle size: Small, dense LDL particles are more atherogenic than large, buoyant particles. However, the clinical utility of measuring particle size remains debated.

Inflammatory Markers

High-sensitivity C-reactive protein (hs-CRP): An inflammatory marker that independently predicts cardiovascular events. Elevated hs-CRP suggests inflammatory contributions to risk beyond traditional factors. Useful for refining risk in intermediate-risk individuals. Very elevated hs-CRP may indicate infection or other inflammatory conditions unrelated to atherosclerosis.

Glucose Metabolism

Fasting glucose: Screens for diabetes and prediabetes. Diabetes dramatically increases CAD risk.

HbA1c: Reflects average glucose over 2-3 months. Diagnoses diabetes and prediabetes; monitors glycemic control in diabetics. Higher HbA1c in diabetics correlates with higher cardiovascular risk.

Fasting insulin: Elevated fasting insulin indicates insulin resistance, which precedes diabetes and is associated with increased CAD risk.

Other Relevant Tests

Kidney function (creatinine, eGFR): Chronic kidney disease dramatically increases cardiovascular risk and affects medication choices.

Liver function: Baseline assessment before starting statins; fatty liver disease is associated with increased cardiovascular risk.

Thyroid function: Hypothyroidism causes dyslipidemia; hyperthyroidism can cause arrhythmias.

Complete blood count: Anemia can worsen angina; polycythemia increases blood viscosity.

Cardiac biomarkers (troponin, BNP): Used in acute settings to diagnose heart attack or assess heart failure, not for routine screening.

---

Diagnosis of Coronary Artery Disease

Clinical Assessment

Diagnosis begins with careful history and physical examination. The characteristics of chest pain, risk factor profile, and physical findings guide further evaluation.

Electrocardiogram (ECG)

A resting ECG may show evidence of prior heart attack, ischemia, or other abnormalities. However, a normal resting ECG does not exclude CAD — many individuals with significant disease have normal ECGs at rest.

Stress Testing

Stress testing evaluates the heart’s response to increased workload:

Exercise stress test: Individual exercises on treadmill or bicycle while ECG is monitored. Positive test shows ECG changes suggesting ischemia. Good for individuals who can exercise adequately.

Stress imaging: Combines stress (exercise or pharmacological) with imaging (echocardiography or nuclear perfusion). More sensitive and specific than ECG alone. Identifies which areas of heart are ischemic and quantifies extent.

Pharmacological stress: For individuals unable to exercise, medications (adenosine, dobutamine) simulate cardiac stress for imaging studies.

Coronary Calcium Scoring

CT scan without contrast measures calcified plaque in coronary arteries. Calcium is a marker of atherosclerosis — its presence indicates established CAD. Score of zero indicates very low short-term risk; higher scores indicate greater plaque burden and higher risk. Useful for refining risk assessment in intermediate-risk individuals. Does not detect soft, non-calcified plaque and cannot assess stenosis severity.

CT Coronary Angiography

CT scan with contrast visualizes coronary arteries and can identify stenoses, plaque burden, and plaque characteristics. High negative predictive value — if normal, significant CAD is very unlikely. Best for intermediate-risk individuals with atypical symptoms. Radiation and contrast exposure are considerations.

Cardiac Catheterization (Coronary Angiography)

The gold standard for defining coronary anatomy. A catheter is inserted through an artery (usually radial or femoral) and advanced to the coronary arteries. Contrast dye is injected and X-ray images reveal the location and severity of stenoses. Invasive and carries small risks, but provides definitive information and allows intervention (angioplasty/stenting) in the same procedure if indicated.

---

Prevention of Coronary Artery Disease

Prevention is the most powerful approach to CAD. Because atherosclerosis develops over decades, there is an enormous window of opportunity for intervention. Modifying risk factors before disease develops (primary prevention) or before events occur in established disease (secondary prevention) saves lives. Studies estimate that addressing known risk factors could prevent 80-90% of coronary events.

Risk Assessment

Prevention begins with risk assessment. Risk calculators (such as the Pooled Cohort Equations in the U.S. or SCORE2 in Europe) estimate 10-year cardiovascular risk based on age, sex, race, blood pressure, cholesterol, diabetes status, and smoking. Risk categories guide the intensity of preventive measures:

• Low risk: Focus on lifestyle modification; pharmacotherapy usually not needed
• Intermediate risk: Lifestyle modification essential; consider additional testing (coronary calcium, Lp(a)) to refine risk; shared decision-making about statin therapy
• High risk: Aggressive lifestyle modification plus pharmacotherapy (statins, blood pressure medications)
• Very high risk (established CAD): Maximum intensity lifestyle and medical therapy

Risk assessment should be performed for all adults starting at age 40, or earlier if risk factors are present.

Lifestyle Modification

Lifestyle changes are the foundation of CAD prevention and treatment. They are effective, have no side effects, and provide benefits beyond cardiovascular health.

Diet: Dietary patterns emphasizing vegetables, fruits, whole grains, legumes, nuts, fish, and healthy oils (Mediterranean or DASH-style diets) reduce CAD risk by 25-30%. These diets are naturally low in saturated fat, trans fat, sodium, and added sugars. Specific beneficial components include fiber, which improves lipids; omega-3 fatty acids from fish, which reduce triglycerides and have anti-inflammatory effects; and polyphenols from plants, which have antioxidant properties.

Dietary recommendations include:

• Replace saturated fat (red meat, butter, full-fat dairy) with unsaturated fat (olive oil, nuts, avocado, fish)
• Eliminate trans fat (partially hydrogenated oils found in some processed foods)
• Emphasize fiber-rich foods (vegetables, whole grains, legumes)
• Limit sodium to reduce blood pressure
• Limit added sugars and refined carbohydrates
• Limit red and processed meat

Physical activity: Regular exercise reduces CAD risk by 30-40%. Current guidelines recommend at least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming) or 75 minutes of vigorous activity (running, vigorous cycling). Any activity is better than none — even short bouts of activity accumulate benefit. Resistance training provides additional benefits for metabolic health and should be performed twice weekly. Prolonged sitting is independently harmful; breaking up sedentary time is beneficial.

Smoking cessation: Stopping smoking is the single most effective lifestyle intervention for smokers. The cardiovascular benefits begin within hours (heart rate and blood pressure decrease) and accumulate over time. Within 1-2 years, excess risk is substantially reduced; by 10-15 years, risk approaches that of never-smokers. All smokers should be counseled to quit at every healthcare encounter. Pharmacotherapy (nicotine replacement therapy, bupropion, varenicline) doubles or triples quit rates and should be offered. Electronic cigarettes are not recommended as cessation aids, and their cardiovascular effects remain uncertain.

Weight management: Achieving and maintaining healthy weight improves lipids, blood pressure, glucose metabolism, and inflammation. Even modest weight loss (5-10% of body weight) produces meaningful improvements in risk factors. A combination of diet, physical activity, and behavioral support is most effective. For those unable to achieve adequate weight loss through lifestyle alone, medications or bariatric surgery may be considered.

Alcohol: If consumed, alcohol should be limited to moderate amounts (up to one drink daily for women, up to two for men). The previous belief that light drinking is protective has been questioned by recent research; abstainers should not be encouraged to start drinking for cardiovascular benefit. The harms of excess consumption (hypertension, cardiomyopathy, atrial fibrillation, liver disease) are clear.

Stress management and sleep: Chronic stress and inadequate sleep contribute to CAD risk through behavioral pathways (poor diet, physical inactivity, smoking) and physiological mechanisms (elevated cortisol, inflammation, elevated blood pressure). While evidence for specific stress reduction interventions is limited, addressing sleep disorders (especially obstructive sleep apnea), treating depression and anxiety, and practicing stress management techniques are reasonable components of cardiovascular risk reduction.

Blood Pressure Control

Hypertension is a major modifiable risk factor for CAD, stroke, heart failure, and kidney disease. The relationship between blood pressure and cardiovascular risk is continuous — there is no threshold below which lower pressure isn’t beneficial. Target blood pressure for most adults is below 130/80 mmHg, though individual targets may vary.

Blood pressure management follows a stepwise approach:

1. Lifestyle modification: Effective for all individuals, sufficient for some
   • Weight loss — each kilogram lost reduces systolic BP
   • DASH diet — rich in fruits, vegetables, whole grains, low-fat dairy; low in saturated fat and sodium
   • Sodium reduction — target intake below 2,300 mg/day
   • Physical activity — lowers BP
   • Alcohol limitation
   • Potassium intake — from dietary sources
2. Pharmacotherapy: Added when lifestyle is insufficient
   • First-line agents: ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics
   • Many individuals require two or more medications
   • Choice is guided by comorbidities and individual response

Consistent medication adherence and regular monitoring are essential. Home blood pressure monitoring empowers individuals and improves outcomes.

Cholesterol Management

Lowering LDL cholesterol is one of the most evidence-based interventions in preventive medicine. The relationship between LDL and atherosclerosis is causal and dose-dependent — the lower the LDL and the longer the duration of low LDL, the lower the risk. Studies consistently show that cardiovascular event reduction is proportional to the absolute reduction in LDL, with benefit increasing in proportion to the magnitude of reduction — a principle captured in the phrase “lower is better.”

Statins are the cornerstone of cholesterol management. They inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL by 30-50% depending on the statin and dose. Statins also have pleiotropic effects including plaque stabilization and anti-inflammatory properties. They have proven mortality benefits in high-risk populations and are among the most studied medications in medicine.

Statin intensity is categorized as:

• High-intensity: Lowers LDL by 50% or more (atorvastatin 40-80 mg, rosuvastatin 20-40 mg)
• Moderate-intensity: Lowers LDL by 30-49% (atorvastatin 10-20 mg, simvastatin 20-40 mg, others)

Additional lipid-lowering agents may be added if LDL goals are not achieved with statins alone:

• Ezetimibe: Blocks cholesterol absorption in the intestine; adds 15-20% LDL reduction
• PCSK9 inhibitors: Monoclonal antibodies that dramatically lower LDL (50-60% additional reduction); reserved for high-risk individuals not at goal on other therapies or those with familial hypercholesterolemia
• Bempedoic acid: Alternative for statin-intolerant individuals
• Inclisiran: siRNA therapy reducing PCSK9 production; given twice yearly

Treatment intensity is guided by risk: higher-risk individuals benefit from more aggressive LDL lowering. In secondary prevention (established CAD), guidelines recommend achieving very low LDL levels, with some recommending greater than 50% reduction from baseline. The appropriate targets are determined by shared decision-making between individual and clinician based on individual risk.

Diabetes Management

Good glycemic control reduces microvascular complications; control of associated risk factors (blood pressure, lipids) reduces macrovascular events. Certain diabetes medications (SGLT2 inhibitors, GLP-1 receptor agonists) have demonstrated cardiovascular benefits beyond glucose lowering.

Aspirin

Aspirin reduces the risk of thrombotic events by inhibiting platelet aggregation. In secondary prevention (individuals with established CAD), low-dose aspirin is standard unless contraindicated. In primary prevention, the benefit-to-risk ratio is less favorable; aspirin is now recommended selectively for higher-risk individuals after shared decision-making, considering bleeding risk.

---

Treatment of Established CAD

Medical Therapy

individuals with established CAD benefit from optimal medical therapy (OMT), which typically includes:

• Antiplatelet therapy: Aspirin for all; dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) after acute events or stenting
• Statin therapy: High-intensity statin for maximum LDL reduction
• Blood pressure control: ACE inhibitors or ARBs have additional benefits beyond BP lowering
• Beta-blockers: Reduce myocardial oxygen demand; particularly important after heart attack
• Nitroglycerin: For symptom relief in angina
• Additional anti-anginal medications: Calcium channel blockers, ranolazine as needed for symptom control

Revascularization

When medical therapy is insufficient or anatomy is high-risk, revascularization restores blood flow:

Percutaneous coronary intervention (PCI): Catheter-based procedure where a balloon is inflated to open the narrowed artery, and a stent (metal mesh tube) is placed to keep it open. Drug-eluting stents reduce re-narrowing. PCI is the primary treatment for STEMI and is used for symptom relief in stable CAD when optimal medical therapy is insufficient.

Coronary artery bypass grafting (CABG): Open-heart surgery where blood vessels from elsewhere in the body (usually mammary artery and saphenous vein) are used to bypass blocked coronary arteries. CABG provides more complete revascularization and is preferred for certain anatomical patterns (left main disease, three-vessel disease, especially with diabetes).

The choice between PCI and CABG depends on anatomy, individual characteristics, and shared decision-making. Both require ongoing medical therapy and risk factor modification — they address symptoms and improve prognosis in selected individuals but don’t cure the underlying atherosclerotic process.

Cardiac Rehabilitation

After a heart attack or revascularization, cardiac rehabilitation programs provide supervised exercise, education, and support. Cardiac rehab reduces mortality, improves quality of life, and facilitates return to normal activities. It is underutilized — all eligible individuals should be referred.

---

Living with Coronary Artery Disease

A diagnosis of CAD is life-changing but not life-ending. With appropriate treatment and lifestyle modification, many people with CAD live full, active lives. The keys are adherence to prescribed therapies, sustained lifestyle changes, regular follow-up, and awareness of warning signs.

Adherence to Medical Therapy

Medications only work if taken consistently. Yet studies show that adherence to cardiovascular medications is often poor — within a year of a heart attack, many individuals have stopped taking prescribed medications. This non-adherence is associated with increased mortality and recurrent events.

Barriers to adherence include:

• Complexity of regimens (multiple pills, multiple times daily)
• Side effects (real or perceived)
• Cost of medications
• Lack of understanding about why each medication is important
• Feeling well and questioning need for continued treatment
• Concerns about long-term medication use

Strategies to improve adherence include:

• Simplifying regimens (once-daily medications, pill boxes, combination pills)
• Understanding the purpose and benefits of each medication
• Discussing and addressing side effects promptly
• Using reminder systems (alarms, apps)
• Addressing cost issues (generic alternatives, individual assistance programs)
• Regular follow-up with healthcare providers

Lifestyle Maintenance

The lifestyle modifications that prevent CAD also slow its progression and reduce events in established disease. Diet, exercise, smoking cessation, and stress management remain important after diagnosis — they are lifelong practices, not temporary interventions.

Sustaining lifestyle changes is challenging. Strategies include:

• Setting realistic, incremental goals
• Building habits gradually
• Finding enjoyable forms of physical activity
• Engaging family and social support
• Anticipating and planning for challenges (holidays, travel, stress)
• Viewing setbacks as learning opportunities, not failures

Recognizing Warning Signs

Individuals with CAD should know the signs of worsening disease or acute events:

• New or changing angina: New chest discomfort, or familiar angina occurring with less exertion, lasting longer, or not responding to nitroglycerin as expected
• Shortness of breath: Particularly new or progressive exertional dyspnea
• Decreased exercise capacity: Fatigue or symptoms occurring at lower activity levels than before
• Heart attack warning signs: Severe, persistent chest pain; shortness of breath; sweating; nausea; lightheadedness — these require immediate emergency response (call emergency services)

Individuals should have a clear action plan for symptoms, including when to use nitroglycerin, when to call their doctor, and when to call emergency services.

Regular Follow-up

Ongoing care with a primary care physician and/or cardiologist ensures risk factors are controlled, medications are optimized, and complications are detected early. Typical follow-up includes:

• Regular office visits (frequency depends on stability and risk)
• Blood pressure monitoring (home and office)
• Periodic blood tests: lipid panel (to verify LDL is at goal), glucose/HbA1c, kidney function, liver function (for those on statins)
• Periodic ECG or stress testing as indicated
• Assessment of symptoms and functional status
• Review of medications and adherence
• Reinforcement of lifestyle recommendations

Emotional and Psychological Aspects

A diagnosis of CAD, particularly after a heart attack, often triggers significant psychological responses:

• Anxiety about future events
• Depression (affects 15-20% of heart attack survivors)
• Fear of physical activity
• Changes in self-image and identity
• Relationship and sexual concerns

These reactions are normal but should be addressed. Depression after a heart attack is associated with worse outcomes and should be treated. Cardiac rehabilitation programs provide psychological support alongside exercise training. Individual counseling or support groups may be helpful.

---

Key Takeaways

Coronary artery disease, though the world’s leading cause of death, is largely preventable through identification and modification of risk factors. Early intervention — ideally before significant atherosclerosis develops — offers the greatest benefit.

Key points to remember:

• CAD develops over decades before causing symptoms — prevention must start early
• Major risk factors include high LDL, hypertension, diabetes, smoking, obesity, and family history
• Most risk factors are modifiable through lifestyle changes and medical treatment
• Blood testing is essential: lipid panel, glucose/HbA1c, and consider apoB, Lp(a), hs-CRP
• Lifestyle modification (diet, exercise, smoking cessation, weight management) is foundational
• Statins reduce LDL cholesterol and cardiovascular events; benefit depends on baseline risk
• Blood pressure control, diabetes management, and aspirin (in appropriate individuals) are also important
• Symptoms of angina or heart attack require prompt medical evaluation
• Treatment of established CAD includes optimal medical therapy and, when needed, revascularization
• Ongoing risk factor control and adherence to therapy are essential even after treatment

Understanding your cardiovascular risk — through risk factor assessment, blood testing, and discussion with your healthcare provider — is the first step toward preventing coronary artery disease and its consequences.